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Background: Most patients with gastroesophageal reflux disease experience symptomatic relapse after stopping
acid-suppressive medication. The aim of this study was to compare willingness to continue treatment with
esomeprazole on-demand versus continuous maintenance therapy for symptom control in patients with
non-erosive reflux disease (NERD) after 6 months.
Methods: This multicenter, open-label, randomized, parallel-group study enrolled adults with NERD who were
heartburn-free after 4 weeks’ treatment with esomeprazole 20 mg daily. Patients received esomeprazole 20 mg
daily continuously or on-demand for 6 months. The primary variable was discontinuation due to unsatisfactory
treatment. On-demand treatment was considered non-inferior if the upper limit of the one-sided 95 % confidence
interval (CI) for the difference between treatments was <10 %.
Results: Of 877 patients enrolled, 598 were randomized to maintenance treatment (continuous: n = 297;
on-demand: n = 301). Discontinuation due to unsatisfactory treatment was 6.3 % for on-demand and 9.8 % for
continuous treatment (difference −3.5 % [90 % CI: −7.1 %, 0.2 %]). In total, 82.1 and 86.2 % of patients taking
on-demand and continuous therapy, respectively, were satisfied with the treatment of heartburn and regurgitation
symptoms, a secondary variable (P = NS). Mean study drug consumption was 0.41 and 0.91 tablets/day, respectively.
Overall, 5 % of the on-demand group developed reflux esophagitis versus none in the continuous group (P < 0.0001).
The Gastrointestinal Symptom Rating Scale Reflux dimension was also improved for continuous versus on-demand
treatment. Esomeprazole was well tolerated.
Conclusions: In terms of willingness to continue treatment, on-demand treatment with esomeprazole 20 mg was
non-inferior to continuous maintenance treatment and reduced medication usage in patients with NERD who had
achieved symptom control with initial esomeprazole treatment.
Trial registration: ClinicalTrials.gov identifier (NCT number): NCT02670642; Date of registration: December 2015.
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Gastroesophageal reflux disease (GERD) is a chronic
condition characterized by a range of symptoms, the
most important of which are heartburn and regurgita-
tion [1, 2]. Population-based studies have shown that
these symptoms affect as many as 20 % of people on a
weekly basis [3]. Although GERD is associated with re-
flux esophagitis, which can be detected and confirmed
by esophageal endoscopy, as many as 70 % of patients
with GERD display no such endoscopic findings and are
thus termed as having endoscopy-negative or non-
erosive reflux disease (NERD) [4]. Despite the absence of
esophagitis, many of these patients experience a signifi-
cant impairment in their health-related quality of life
(HRQoL), similar to that experienced by patients with
reflux esophagitis [4–6].
As the severity of symptoms generally correlates with
esophageal acid exposure [7, 8], the most effective treat-
ment for GERD, including NERD, is acid-suppressive
therapy with a proton pump inhibitor (PPI) [9]. It has
been shown that continuous maintenance treatment
with the PPI esomeprazole (20 mg once daily) provides
more effective acid suppression and maintained intragas-
tric pH >4 for a greater period of time than maintenance
omeprazole, lansoprazole, pantoprazole or rabeprazole
in patients with GERD [10, 11]. In addition, a study by
Talley et al. showed that, in patients with NERD,
6 months’ on-demand treatment with esomeprazole
20 mg controlled symptoms in 92 % of patients who
were using only 33 % of the medication needed for daily
continuous treatment [12]. In our study, we compared
the efficacy of on-demand versus continuous esomepra-












20 mg od 
continuous
RandomiEndoscopy
Fig. 1 Study design. Abbreviations: NERD, non-erosive reflux disease (withohad complete resolution of heartburn symptoms follow-
ing initial treatment with esomeprazole) in terms of the
willingness of patients to continue therapy.
Methods
Patients
Patients presenting to their general practitioner or
gastrointestinal (GI) specialist with symptoms suggestive
of GERD and with heartburn as their predominant
symptom for longer than 6 months were considered for
study entry. In addition, patients were included if they
met the following inclusion criteria: age ≥18 years
(Austria, ≥19 years); heartburn occurring for ≥4 days
during the last 7 days before endoscopy; or, if PPI ther-
apy had been started within the last 7 days before endos-
copy, heartburn occurring for ≥4 days during the last
7 days before the start of PPI treatment.
Patients were excluded if they had any of the follow-
ing: significant GI disorders or other disorders likely to
affect the outcome of the study; gastroduodenal ulcers
within the previous 2 years; previous esophageal, gas-
tric or duodenal surgery (except closure and oversew-
ing of an ulcer); irritable bowel syndrome; PPI use for
either ≥10 of the 28 days before endoscopy or ≥5 of
the 7 days before endoscopy; use of concomitant ther-
apy likely to affect the outcome of the trial; pregnancy or
lactation; childbearing potential unless taking effective
contraception; and alcohol or drug abuse.
Study design
This was a multicenter, open-label, randomized, parallel-
group study (Fig. 1). Patients were enrolled at 61 centers
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performed in accordance with the most recent
amendment to the Declaration of Helsinki and com-
plied with Good Clinical Practice. At each participat-
ing center, a local independent ethics committee or
institutional review board approved the final study
protocol. Signed informed consent was obtained from
all patients before conducting any specific procedures
for the study.
At visit 1 (week −4), a medical history was taken, and
physical examination and endoscopy were performed.
Endoscopy was performed again at visit 2 (week 0), and
patients with reflux esophagitis detected at either visit
1 or 2 were excluded from randomization. Reflux
esophagitis was defined as endoscopy-confirmed muco-
sal breaks [13]. Helicobacter pylori status was assessed
at visit 1 on two antral and two corpus biopsy speci-
mens. Specimens were evaluated by one central path-
ologist according to the criteria of the Sydney
classification [14]. Patients with positive H. pylori status
did not receive any eradication treatment during the
study period.
All eligible patients underwent an initial (short-term)
treatment period of 4 weeks with esomeprazole 20 mg
tablets once daily (administered as 22.3 mg esomeprazole
magnesium trihydrate). Severity of symptoms (heartburn,
acid regurgitation, dysphagia and epigastric pain) was
assessed as none, mild, moderate or severe at visits 1
(week −4) and 2 (week 0) using standard questions posed
by the investigator. The frequency of heartburn was
also reported. Only patients who were free from heart-
burn at visit 2 (defined as 7 symptom-free days in the
last week of the short-term treatment phase; i.e.,
complete resolution of symptoms) were randomized se-
quentially (1:1) to one of two treatment groups for a 6-
month maintenance treatment phase. Patients in the
on-demand treatment group received esomeprazole
20 mg tablets (up to a maximum of once daily), taken
as needed to adequately control their reflux symptoms;
treatment could be taken to prevent symptoms, to
soothe symptoms, or both. Specific circumstances
prompting each on-demand use of esomeprazole were
not recorded, although at the end of the 6-month treat-
ment period patients were asked whether they had
taken their medicine to soothe or prevent symptoms,
or both. Patients in the continuous treatment group re-
ceived esomeprazole 20 mg tablets once daily continu-
ously (Fig. 1). Randomization was performed using a
computer program at AstraZeneca in balanced blocks
using a blocking size of 2.
Other PPIs and H2-receptor antagonists were not per-
mitted during treatment. Antacids could only be taken
between initial endoscopy and first administration of
study drug.Study measurements and variables
The primary variable was the proportion of patients dis-
continuing the study as a result of unsatisfactory treat-
ment. At clinical visits 2 to 5 (weeks 0, 8, 16 and 24 of
the maintenance treatment phase) the investigator con-
firmed with the patient if he/she wished to continue
with the treatment and, if not, the date and reasons for
discontinuation were recorded. Following discontinu-
ation of esomeprazole, patients were treated at the dis-
cretion of their investigator with medicines that were
available in their country.
Secondary variables included the reasons given for
treatment discontinuation, including: dissatisfaction
with symptom control, the method of administration
(on-demand or continuous) or taste/size of the pill; ad-
verse events (AEs); protocol non-compliance; inclusion
criteria not fulfilled (retrospective); patient lost to follow-
up; improvement/recovery as evaluated by the investiga-
tor; or other reason specified by the investigator.
Treatment satisfaction was evaluated using a standard-
ized questionnaire completed by patients at visits 2 to 5
(weeks 0, 8, 16 and 24 of the maintenance treatment
phase), or at premature discontinuation. The question-
naire comprised three questions: “How satisfied or dis-
satisfied are you with the effect of the drug?”; “How
satisfied or dissatisfied are you with the way of taking
the drug?”; and “Overall, how satisfied or dissatisfied are
you with the way of treating your heartburn and regurgi-
tation symptoms?”. Patients were asked to give their an-
swers as “completely satisfied”, “quite satisfied”, “neither
satisfied nor dissatisfied”, “quite dissatisfied” or “com-
pletely dissatisfied”. For the purpose of this analysis, “sat-
isfied” was defined as the sum of the upper two ratings
(“completely satisfied” and “quite satisfied”).
The intake of study medication was registered using
the MEMS® device, which utilizes a microelectronic re-
corder recessed in the cap of a drug container (Medical
Event Monitoring System, Aardex, Zug, Switzerland). At
each opening and closure of the container, the date and
time of day was automatically recorded. This informa-
tion was analyzed at the end of the study.
The evaluation of patient-reported outcomes focused
on reflux symptoms and the impact on patients’ quality
of daily life. Symptom assessments were carried out
using a standardized patient-reported outcomes ques-
tionnaire, the Gastrointestinal Symptom Rating Scale
(GSRS), which has been validated in symptomatic GERD
[15]. The GSRS consists of 15 GI symptoms grouped
into 5 dimensions. Each dimension is scored on a 7-
point scale, with a lower score indicating a lower per-
ceived symptom severity. HRQoL assessments were
made using the Quality of Life in Reflux and Dyspepsia
(QOLRAD) instrument [16, 17], which was specifically
developed for patients with symptoms of reflux and
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items grouped into 5 dimensions representing different
aspects of the daily life of patients with GERD. The
questionnaire uses a similar 7-point scoring system to
the GSRS; however, a lower score indicates a more se-
vere impact on daily functioning. The GSRS and QOL-
RAD questionnaires were completed by the patients
prior to treatment starting at visit 1 and at all subse-
quent visits. The changes in these parameters from start
of the short-term and maintenance treatment phases to
the end of the study were assessed and compared be-
tween the two treatments.
Data for all patient-reported outcomes were collected
electronically by patients using a hand-held computer
(Newton MessagePad 130/2000; Apple Computer, Inc.,
Cupertino, CA, USA). Use of an electronic question-
naire, rather than a paper-based format, was selected in
view of the associated benefits of completeness of data,
speed of data flow and ease of data handling [18].
Safety and tolerability
AE and serious AE (SAE) assessments were recorded
throughout the short-term and maintenance treatment
phases of the study (visits 1–5). Blood samples for la-
boratory screening were taken before administration of
the study drug (at visit 1) and at study end point or pre-
mature discontinuation.
Endoscopic assessment
An endoscopic assessment of the esophageal mucosa
was performed at visits 1 (or 7 days before) and 5 (end
of study), and for all patients who left the study prema-
turely. The Los Angeles (LA) classification system [19]
was used to grade the appearance of mucosal breaks.
Statistical analysis
The proportion of patients who were free of heartburn
at the end of the initial 4-week treatment phase was cal-
culated for the safety population, which comprised all
patients who took at least one dose of study drug and
for whom post-dose information was available. All pa-
tients randomized to maintenance treatment were in-
cluded in the intention-to-treat (ITT) analysis set, and
the primary variable was analyzed for these patients. ITT
data were analyzed using the last-visit-carried-forward
method for those patients who discontinued prematurely,
and all patients who discontinued were regarded as
having discontinued due to unsatisfactory treatment.
ITT patients were included in the per-protocol (PP)
analysis set if they were assessed for the primary vari-
able. Patients were excluded from the PP population
due to: violation of the inclusion/exclusion criteria;
treatment with disallowed concomitant medication;compliance less than 75 % in the treatment period; or
other deviations from study procedures.
Estimates and two-sided 90 % confidence intervals
(CIs) were calculated for the difference between the on-
demand and continuous treatment groups in the propor-
tion of patients who discontinued prematurely because
of dissatisfaction with study treatment. On-demand
treatment was considered to be non-inferior to continu-
ous treatment if the one-sided 95 % CI for the difference
between treatments, shown by the upper bound of the
two-sided 90 % CI, was less than 10 %, as pre-specified
in the clinical study protocol [12, 20]. The difference be-
tween the groups in the proportion of patients who dis-
continued (overall and due to an AE) was compared
using Chi-square tests with Yates’ correction.
The secondary variables were analyzed for the ITT
population only. The reasons for discontinuation from
treatment and drug usage (date and time recorded by
the MEMS® device) were recorded descriptively.
Results from the treatment satisfaction questions were
presented using estimates for the proportion of satis-
fied patients for the two treatment groups. In addition,
estimates and two-sided 95 % CIs (based on normal ap-
proximation) for the treatment difference in the pro-
portion of satisfied patients were assessed.
For patient-reported changes in symptoms and HRQoL,
the changes from baseline visit 1 (week −4) to end point
and from visit 2 (week 0) to end point were calculated for
the separate dimensions of GSRS and QOLRAD with
two-sided 95 % CIs. The differences between the two
treatment groups were compared for each dimension
using analysis of variance.
Safety data were presented for the safety population
(as defined above).Determination of sample size
Sample size was calculated from numbers needed to
show that on-demand treatment was non-inferior to con-
tinuous treatment based on the proportion of patients
who would discontinue the study prematurely because of
unsatisfactory therapy. As outlined above, on-demand
treatment was defined as non-inferior to continuous treat-
ment if the upper bound of the two-sided 90 % CI for the
difference in proportions (on-demand minus continuous)
was less than 10 %.
With a sample size of 275 patients in each treatment
group, a one-sided test of proportions at the 5 % level
had 90 % power to reject the hypothesis that on-
demand treatment is inferior to continuous treatment.
With an estimated 10 % non-evaluable patients and as-
suming that only 60 % of the patients would be ran-
domized (conservative estimates based on data from
previous studies), it was calculated that 1020 patients
Bayerdörffer et al. BMC Gastroenterology  (2016) 16:48 Page 5 of 12would be required in the initial treatment phase to yield
sufficient power.
Results
Patient disposition and demographics
Patients were enrolled at 6 centers in Austria (n = 65),
27 in France (n = 211), 14 in Germany (n = 182), 9 in
South Africa (n = 289) and 5 in Spain (n = 130). Patient
disposition through each stage of the study is shown in
Fig. 2. In total, 877 patients were enrolled at visit 1 and
598 (68 %) eligible patients were randomized to main-
tenance treatment at visit 2. The safety population com-
prised 674 patients during the short-term treatment
phase and 595 patients (on-demand, n = 301; continu-
ous, n = 294) during the maintenance treatment phase.
During the 4-week short-term treatment period, a high
proportion of patients (619/674, 92 %) were free of
heartburn (investigator-assessed); this was one of the eli-
gibility criteria for the maintenance treatment phase of
the study.
All 598 patients randomized to the maintenance treat-
ment phase were included in the ITT analysis and 483 ofFig. 2 Flow diagram of patients’ disposition through the stages of the studthese fulfilled the criteria for inclusion in the PP analysis.
Of the 279 patients who were enrolled into the study
but not randomized, 202 did not fulfil the eligibility cri-
teria (most because of the presence of esophagitis at
endoscopic examination at either the enrollment or
randomization visit), including 44 patients who had
heartburn for at least one day in the week prior to
randomization. Of the 115 patients excluded from the
PP analysis, 36 had received disallowed medication dur-
ing maintenance treatment. Overall, the maintenance
treatment groups were well balanced with respect to
demographic and baseline characteristics (Table 1).
When viewed by country, the demographic data were
similar in terms of age and gender. Austria, Germany and
France showed similar proportions of patients who were
H. pylori-positive (26.7, 28.8 and 34.2 %, respectively).
However, the proportions for South Africa and Spain were
noticeably higher (63.4 and 54.7 %, respectively).
Primary variable
In total, 48 (8.0 %) patients discontinued from the study
prematurely, 19 (6.3 %) in the on-demand treatmenty. Abbreviations: ITT, intention-to-treat; PP, per-protocol





Men, n (%) 122 (40.5) 130 (43.8)
Women, n (%) 179 (59.5) 167 (56.2)
Ethnicity, n (%)
White 259 (86.0) 255 (85.9)
Black 14 (4.7) 10 (3.4)
Asian 1 (0.3) 4 (1.3)
Othera 27 (9.0) 28 (9.4)
Age (y), mean ± SD 48.2 ± 13.6 47.6 ± 15.1
Height (cm), mean ± SD 167.0 ± 9.1 167.0 ± 9.9
Weight (kg), mean ± SD 75.1 ± 14.3 75.8 ± 14.7
Hiatal hernia, n (%) 96 (31.9) 108 (36.4)
Days with heartburn, n (%)
4 d 26 (8.6) 31 (10.4)
5 d 55 (18.3) 46 (15.5)
6 d 46 (15.3) 42 (14.1)
7 d 174 (57.8) 178 (59.9)
Severity of heartburn, n (%)
Mild 21 (7.0) 19 (6.4)
Moderate 165 (54.8) 153 (51.5)
Severe 115 (38.2) 125 (42.1)
Severity of acid regurgitation, n (%)
None 82 (27.2) 63 (21.2)
Mild 68 (22.6) 76 (25.6)
Moderate 95 (31.6) 95 (32.0)
Severe 56 (18.6) 63 (21.2)
Severity of epigastric pain, n (%)
None 133 (44.2) 129 (43.4)
Mild 96 (31.9) 81 (27.3)
Moderate 54 (17.9) 64 (21.5)
Severe 18 (6.0) 23 (7.7)
Severity of dysphagia, n (%)
None 265 (85.0) 255 (85.9)
Mild 28 (9.3) 22 (7.4)
Moderate 14 (4.7) 14 (4.7)
Severe 3 (1.0) 6 (2.0)
Helicobacter pylori-positive, n (%) 125 (41.5) 130 (43.8)
aIncluding patients of mixed ethnicity
Abbreviation: SD standard deviation







Eligibility criteria not fulfilled 4 (1.3) 6 (2.0)
Adverse events 1 (0.3) 6 (2.0)
Improvement/recovery 0 2 (0.7)
Lost to follow-up 6 (2.0) 7 (2.4)
Protocol non-compliance 2 (0.7) 2 (0.7)
Unsatisfied with symptom control 3 (1.0) 2 (0.7)
Other 3 (1.0) 4 (1.3)
Total 19 (6.3) 29 (9.8)a
aDifference versus on-demand treatment was not significant (P = 0.15)
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(P = 0.15). In the ITT analysis, all premature discontinu-
ations were regarded as being due to unsatisfactory
treatment. The distribution of reasons for discontinu-
ation was similar in the two treatment groups (Table 2).
Five patients (on-demand, n = 3; continuous, n = 2)actively reported that they discontinued the study be-
cause of unsatisfactory control of symptoms and no pa-
tient in either group discontinued because of
dissatisfaction with the way of taking the drug or the
taste/size of the tablet.
For the primary variable (discontinuation because of
unsatisfactory treatment), on-demand treatment was
non-inferior to continuous treatment, as shown by the
upper confidence limit (90 % CI) of the difference be-
tween on-demand and continuous treatment being less
than 10 % in both the ITT and PP analyses (Table 3).
The number of patients who discontinued prematurely
from the study in each country was: Austria, 2 (3.3 %);
France, 13 (8.5 %); Germany, 10 (6.8 %); South Africa,
14 (8.5 %); and Spain, 9 (12.0 %). When the primary
variable was assessed by H. pylori status, a similar num-
ber of patients discontinued prematurely from the study
whether they were H. pylori-positive (21 [8.2 %]) or not
(27 [7.9 %]).
Secondary variables
There was no statistically significant difference between
the two treatment groups regarding the proportion of pa-
tients who responded that they were satisfied overall with
the way their heartburn and regurgitation symptoms were
being treated at 6 months (82.1 and 86.2 % for on-demand
and continuous treatment, respectively; difference −4.1 %
[95 % CI: −10.0 %, 1.7 %]). Similarly, there was no statisti-
cally significant difference in the proportion of patients sat-
isfied with the way they were taking the treatment (81.7
and 82.8 % for on-demand and continuous treatment, re-
spectively; difference −1.1 % [95 % CI: −7.2 %, 5.0 %]) and
the effect of treatment (78.7 and 84.8 %, respectively; differ-
ence −6.1 % [95 % CI: −12.3 %, 0.1 %]).
Among patients with evaluable data (on-demand, n =
295; continuous, n = 286), mean drug usage over the 6-
month study period was 0.41 (standard deviation [SD],
0.25) tablets (doses) per day in the on-demand treatment
Table 3 Percentage of patients discontinuing due to unsatisfactory
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ous treatment group. Most patients took their medica-
tion in the morning (on-demand, 54.2 %; continuous,
72.5 %). In the on-demand treatment group, an analysis
of reasons for taking the medication showed that more
patients took their medication to soothe rather than to
prevent symptoms (Table 4). However, most patients
took medication to prevent symptoms at least once dur-
ing the study.
The final endoscopy showed that most patients
remained free of reflux esophagitis at the end of the 6-
month treatment period; 15 patients (5 %), all in the on-
demand treatment group, had endoscopic evidence of
mucosal breaks at the end of the study (P < 0.0001 ver-
sus continuous treatment). Of these patients, 14 had LA
grade A esophagitis and 1 had LA grade B.
From baseline to the end of the 4-week short-term
treatment period (visit 1 to visit 2), large improvements
in the GSRS Indigestion, Abdominal Pain and Reflux di-
mensions and in all QOLRAD dimensions were ob-
served. During the randomized part of the study
(maintenance therapy), further small improvements inTable 4 Reasons for drug intake in the esomeprazole on-demand
treatment arm (intention-to-treat population, n = 301)
Have you taken your medicine to soothe
or prevent symptoms?
Patients [n (%)]
To soothe 85 (28.2)
Mainly to soothe, sometimes to prevent 66 (21.9)
To both soothe and prevent 59 (19.6)
Mainly to prevent, sometimes to soothe 28 (9.3)
To prevent 15 (5.0)
Missing 48 (15.9)scores were seen for the GSRS Indigestion and Abdom-
inal pain dimensions in the continuous treatment group.
Small improvements were also seen from baseline to the
end of short-term treatment and to the end of mainten-
ance treatment for the GSRS Diarrhea and Constipation
dimensions. These improvements were evident in both
the on-demand and continuous treatment groups. The
mean GSRS scores at baseline, the end of short-term
treatment and the end of maintenance treatment are
shown in Fig. 3a. The estimated differences in the
change in GSRS scores from baseline to the end of
maintenance treatment between the continuous and
on-demand treatment groups all favored continuous
treatment: Diarrhea, 0.09 (P = 0.160); Indigestion, 0.25
(P = 0.002); Constipation, 0.14 (P = 0.050); Abdominal
pain, 0.25 (P = 0.001); and Reflux, 0.54 (P < 0.001) (Fig. 3a).
The estimated difference between the treatment groups
in the Reflux dimension was of a magnitude considered
to be clinically relevant. Mean QOLRAD scores at base-
line and at the end of the short-term and maintenance
treatment phases are shown in Fig. 3b. The estimated
differences in the change from baseline to the end of
maintenance treatment between the continuous and
on-demand treatment groups were: Emotional, −0.28
(P < 0.001); Sleep disturbance, −0.28 (P < 0.001); Food/
drink problems, −0.38 (P < 0.001); Physical/social func-
tioning, −0.18 (P = 0.001); and Vitality, −0.31 (P < 0.001);
all differences favored continuous treatment (Fig. 3b).Safety
Overall, the AE profile was similar between the two
treatment groups, and the majority of AEs were mild or
moderate in intensity. AEs were reported by 16.7 % of
patients during the short-term treatment phase, and 36.2
and 35.4 % of patients during the on-demand and con-
tinuous maintenance phases, respectively. The most
commonly reported AEs in the maintenance treatment
phase were GI in nature (Table 5). There were no deaths
during the study. In the maintenance phase, 1 patient in
the on-demand treatment group and 7 patients in the
continuous treatment group discontinued study treat-
ment due to an AE (P = 0.07).
SAEs were recorded for 4 patients in the on-demand
treatment group and 11 patients in the continuous treat-
ment group. With the exception of fracture, which oc-
curred in 2 patients (1 humerus and 1 fibula), all SAEs
occurred in 1 patient each (continuous treatment group:
chest pain with dyspnea, renal pain, pulmonary embol-
ism, aggravated angina pectoris, respiratory infection
and hepatocellular damage, anemia, hernia [interverte-
bral disc], gastroenteritis and sinusitis; on-demand treat-
ment group: meningitis, colon carcinoma, gastroenteritis












































































































































Fig. 3 Mean (a) Gastrointestinal Symptom Rating Scale and (b) Quality of Life in Reflux and Dyspepsia questionnaire scores at baselinea, following
4 weeks’ initial (short-term) treatment with esomeprazole 20 mg once daily, and after maintenance treatment with either on-demand or continuous
esomeprazole for 6 months (intention-to-treat population). aBaseline corresponds to visit 1 (week −4). *P < 0.01 and **P≤ 0.001 for the difference in
the change in scores from baseline to the end of maintenance treatment for continuous versus on-demand treatment groups
Bayerdörffer et al. BMC Gastroenterology  (2016) 16:48 Page 8 of 12the SAEs were considered by study investigators to be
causally related to the study treatment. There were no la-
boratory findings that raised any safety concerns.
Discussion
The results for the primary variable of this multinational
study show that, following an initial 4-week symptom
control phase with esomeprazole 20 mg once daily,
6 months’ on-demand maintenance treatment with
esomeprazole 20 mg was non-inferior to continuous
treatment in terms of patients’ willingness to continue
treatment. The non-inferiority of on-demand versus
continuous treatment was observed in both the ITT
and PP populations, demonstrating that more seriousprotocol violations, such as the use of disallowed treat-
ment to control reflux symptoms, did not appreciably
alter the results for the primary variable. The results of
the primary analysis were further supported by the
finding that there was no statistically significant differ-
ence in the proportions of patients who were satisfied
with the way of taking the drug, and with the effect of
treatment. Indeed, although 18 and 14 % of patients in
the on-demand and continuous treatment groups, re-
spectively, were either indifferent to or dissatisfied with
the way their heartburn and regurgitation symptoms
were being treated, only 3 patients (1.0 %) in the on-
demand treatment group and 2 patients (0.7 %) in the
continuous treatment group discontinued due to
Table 5 Number of patients (%) with the most commonly
reported adverse events in the maintenance treatment phase
(≥2 % in any treatment group; safety population)
Patients [n (%)]
On-demand (n = 301) Continuous (n = 294a)
Flatulence 15 (5.0) 12 (4.1)
Abdominal pain 10 (3.3) 9 (3.1)
Diarrhea 6 (2.0) 9 (3.1)
Constipation 9 (3.0) 5 (1.7)
Viral infection 12 (4.0) 8 (2.7)
Headache 5 (1.7) 7 (2.4)
Respiratory infection 7 (2.3) 6 (2.0)
Gastroenteritis 7 (2.3) 9 (3.1)
Back pain 5 (1.7) 7 (2.4)
Arthralgia 2 (0.7) 6 (2.0)
aThree patients did not take any study drug and were therefore excluded from
the safety population
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somewhat lower than was reported in an earlier 6-
month study (n = 342) examining the efficacy of esome-
prazole on-demand treatment in patients with NERD;
in this study, 14 % of patients discontinued due to in-
sufficient heartburn control (compared with 51 % in
the placebo group) [12].
It is well recognized that rates of remission from endo-
scopic relapse in patients with GERD are directly related
to the degree of acid suppression achieved during ther-
apy [21], and PPIs are the most effective treatment op-
tion in this regard. Among the PPIs, esomeprazole
provides sustained acid suppression [11] that has trans-
lated into higher rates of maintenance of reflux esopha-
gitis healing compared with lansoprazole [22] and
pantoprazole [23]. Esomeprazole 20 mg has also been
approved in Europe for controlling symptoms in patients
with NERD. Indeed, the efficacy of both esomeprazole
40 mg and 20 mg for the maintenance treatment of
NERD has been demonstrated in placebo-controlled tri-
als of continuous [24] and on-demand therapy [12, 20].
The on-demand use of PPIs, including esomeprazole,
has also been compared with continuous use in several
randomized clinical trials of patients with NERD or
GERD [25–30]. Reviews have concluded that on-
demand maintenance treatment with a PPI is an appro-
priate option for patients with mild reflux esophagitis
and those with NERD [31–33], although some authors
have questioned the efficacy of this approach for patients
with healed reflux esophagitis [30]. Indeed, the results of
an observational study suggest that an on-demand ap-
proach may more accurately match patient behavior, as
some patients appear to use their treatment only as re-
quired for symptom control even when prescribed con-
tinuous therapy [34]. Despite extensive research in thisarea, to our knowledge, the present study is the first
multinational study to investigate patient opinion of on-
demand or continuous esomeprazole in patients with
NERD who had responded to initial short-term treat-
ment with a PPI.
Another potential advantage of on-demand treatment
is that it is associated with lower medication use than
continuous treatment. For example, a Japanese study ex-
amined the efficacy of maintenance treatment with
omeprazole on-demand versus continuous in patients
with NERD [35]. Over 24 weeks, mean study drug con-
sumption ranged from 6.2 to 6.9 tablets per week in the
continuous treatment group. In the on-demand treat-
ment group, study drug consumption decreased over
time, from 3.0 to 1.8 tablets per week [35]. In a further
study, patients with NERD received esomeprazole on-
demand or placebo for 6 months [12]. Mean intake of
study medication was 0.34, indicating a 66 % reduction
versus continuous once-daily intake [12]. In line with
these findings, the present study showed that the use of
study medication was reduced by 55 % with on-demand
versus continuous treatment, yet the willingness of pa-
tients to continue therapy was similar to that achieved
with continuous treatment (and with comparable
HRQoL). Mean intake of study medication in the on-
demand treatment group was higher than previously re-
ported [12], although this may have been a result of
patients taking their medication for prevention as well
as relief of symptoms.
The reduction in PPI use with on-demand versus con-
tinuous treatment has important economic implications,
as it is likely to correspond to a reduction in the cost as-
sociated with maintenance treatment [12]. Indeed, in
one study that assessed 6-months’ maintenance treat-
ment with esomeprazole 20 mg on-demand, esomepra-
zole 20 mg once daily or ranitidine 150 mg twice daily,
direct medical costs in patients with GERD were €171.9,
€221.6 and €248.8, respectively. The total costs associ-
ated with maintenance treatment were also lowest for
on-demand esomeprazole (€221.5, €286.5 and €295.8, re-
spectively) [32, 36]. Similarly, in another study, 6-
months’ on-demand treatment with esomeprazole 20 mg
incurred considerably lower direct medical costs than
continuous treatment with omeprazole 20 mg once daily
in GERD patients without esophagitis [37].
There is a known risk of relapse of reflux esophagitis
during maintenance treatment, including on-demand
therapy [31]. Not surprisingly, therefore, a small number
of patients (n = 15), all of whom had been treated with
esomeprazole 20 mg on-demand, had relapse with mu-
cosal breaks at endoscopy after 6 months (the only ob-
jective observation in the present study), all of which
were considered to be mild reflux esophagitis (14 with
grade A and 1 with grade B, according to the LA
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patients may change between a non-erosive stage and re-
flux esophagitis [38, 39]. It is possible, therefore, that a
small proportion of these 15 patients had mild reflux
esophagitis that, at visit 1, was in remission, mediated by
the limited use of PPI therapy that was permitted before
inclusion in the study. Until recently, monitoring the
course of NERD was very difficult; only with the advent
of histological examination of biopsies from the Z-line
has it been possible to monitor progression, regression
and normalization during therapy [40–42]. Indeed, a
previous study in patients with NERD reported that 3
and 6 months of therapy with omeprazole 40 mg led to
complete recovery of dilation of intercellular spaces in
more than 90 % of patients, and that in all cases this was
associated with regression of heartburn [40]. Techno-
logical advances have also meant that NERD can now be
diagnosed based on the absence of esophageal lesions on
endoscopy, with the results of one study reporting that
modern video gastroscopy was able to recognize 76.4 %
of patients with NERD [43]. Combining histology and
endoscopy could, therefore, improve the diagnosis and
monitoring of disease progression during PPI treatment
in patients with NERD.
Relative to on-demand treatment, continuous treat-
ment was perhaps predictably associated with statisti-
cally significant improvements in single parameters of
the GSRS and QOLRAD questionnaires. However, with
the exception of the GSRS Reflux dimension, the differ-
ences in the change in GSRS and QOLRAD scores be-
tween the on-demand and continuous treatment groups
were not deemed to be clinically relevant [44]. Moreover,
patients in the on-demand treatment group took less
medication than those randomized to continuous treat-
ment, and the number of patients willing to continue
treatment at 6 months was comparable between the two
groups. Interestingly, despite the fact that 92 % of pa-
tients were assessed by the investigator as being ‘heart-
burn-free’ at the end of the 4-week short-term treatment
period, patient-reported scores in the GSRS Reflux di-
mension were approximately 1.3 in both the on-demand
and continuous treatment groups. This suggests some
degree of disagreement between investigator and patient
assessments. The difference, however, can probably be
explained by the nature of the GSRS questionnaire; the
GSRS Reflux dimension encompasses both heartburn
and acid regurgitation, whereas in our study, investigator
assessments (and subsequent inclusion in the mainten-
ance phase) related exclusively to heartburn.
In this study, on-demand treatment could be taken to
prevent symptoms, to soothe symptoms, or both. For ex-
ample, patients may have chosen to take their medica-
tion to prevent symptoms in stressful situations, or
before the occurrence of known reflux triggers.Although patients were asked whether they had taken
medication to soothe or prevent symptoms, the exact
reasons for usage of on-demand esomeprazole were not
recorded. To further develop our understanding of pa-
tient behavior, more research into the reasons for taking
on-demand medication is required.
The implications of H. pylori infection on management
of GERD remains controversial [45]. For example, stud-
ies have shown that H. pylori-infected patients with
GERD tend to have higher response rates to acid-
suppressive treatment than H. pylori-negative patients.
More than 40 % of patients in the present study were H.
pylori-positive. This may have implications for the effect-
iveness of on-demand treatment, because H. pylori may
be synergistic in preventing or treating reflux esophagitis
when less than optimal acid suppression is used [46, 47].
Nonetheless, the primary variable was unaffected by H.
pylori status in the present study.
Limitations of this study include its open-label nature
and the fact that patients underwent endoscopy at study
end and upon discontinuation, but not at regular inter-
vals during the study. In addition, the study only in-
cluded NERD patients who had complete resolution of
heartburn symptoms following initial treatment with
esomeprazole; therefore, it is possible that results may
have been less favorable in patients whose response to
short-term treatment was not complete. Strengths of the
study, on the other hand, include the multinational na-
ture of the study population, the use of validated instru-
ments to assess symptoms (GSRS) and quality of life
(QOLRAD), and the use of three different measures of
patient opinion about the impact of on-demand or con-
tinuous treatment (discontinuation due to unsatisfactory
treatment, standardized treatment satisfaction question-
naire and the quality of life questionnaire).
Conclusions
Using the measure ‘willingness to continue treatment’,
6 months of on-demand esomeprazole maintenance treat-
ment was non-inferior to continuous maintenance treat-
ment in patients with NERD who had achieved complete
symptom resolution following 4 weeks of treatment with
esomeprazole. Although continuous treatment gave sig-
nificantly better symptom control than on-demand treat-
ment, as measured by the GSRS questionnaire, only the
difference in the Reflux dimension reached a magnitude
that was clinically relevant. As may have been expected,
medication intake was lower with on-demand treatment,
with obvious potential benefits in terms of cost of treat-
ment and convenience to patients.
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